BACKGROUND: Stereotactic radiosurgery is frequently used for the treatment of brain metastases. This study provides a retrospective evaluation of patients with secondary lesions of the brain treated with stereotactic radiosurgery (SRS) at our institution. AIMS: To provide outcome data from a single institutional experience with SRS and identify any significant prognostic factors in the cohort. METHODS: Sixty-seven patients received first time SRS to 86 intracranial metastases between 2007 and 2010. Sixteen patients were excluded from this study due to the absence of post-treatment neuroimaging, resulting in 51 patients with 64 treated lesions. Of these patients, 37 (72.5%) received SRS electively, while 14 (27.5%) received salvage SRS after brain metastasis progression following whole brain radiotherapy. RESULTS: Median survival for the entire group was 15 months from the date of radiosurgery. Patients without active extracranial disease had statistically significant survival time than those with active extracranial disease (P=0.03). 45 (70.3%) lesions achieved local tumour control in 34 patients (66.7%) with a mean follow-up period of 10.7 months (range 1.7-33.6 months, 95 % confidence interval 6.6-9.8 months). CONCLUSIONS: The results reported in this study equate to those reported in other series consolidating SRS as an effective treatment option with few serious complications. Developments in systemic disease control will see further improvements in overall survival.
BACKGROUND: Stereotactic radiosurgery is frequently used for the treatment of brain metastases. This study provides a retrospective evaluation of patients with secondary lesions of the brain treated with stereotactic radiosurgery (SRS) at our institution. AIMS: To provide outcome data from a single institutional experience with SRS and identify any significant prognostic factors in the cohort. METHODS: Sixty-seven patients received first time SRS to 86 intracranial metastases between 2007 and 2010. Sixteen patients were excluded from this study due to the absence of post-treatment neuroimaging, resulting in 51 patients with 64 treated lesions. Of these patients, 37 (72.5%) received SRS electively, while 14 (27.5%) received salvage SRS after brain metastasis progression following whole brain radiotherapy. RESULTS: Median survival for the entire group was 15 months from the date of radiosurgery. Patients without active extracranial disease had statistically significant survival time than those with active extracranial disease (P=0.03). 45 (70.3%) lesions achieved local tumour control in 34 patients (66.7%) with a mean follow-up period of 10.7 months (range 1.7-33.6 months, 95 % confidence interval 6.6-9.8 months). CONCLUSIONS: The results reported in this study equate to those reported in other series consolidating SRS as an effective treatment option with few serious complications. Developments in systemic disease control will see further improvements in overall survival.
Authors: Minesh P Mehta; May N Tsao; Timothy J Whelan; David E Morris; James A Hayman; John C Flickinger; Michael Mills; C Leland Rogers; Luis Souhami Journal: Int J Radiat Oncol Biol Phys Date: 2005-09-01 Impact factor: 7.038
Authors: Paul W Sperduto; Norbert Kased; David Roberge; Zhiyuan Xu; Ryan Shanley; Xianghua Luo; Penny K Sneed; Samuel T Chao; Robert J Weil; John Suh; Amit Bhatt; Ashley W Jensen; Paul D Brown; Helen A Shih; John Kirkpatrick; Laurie E Gaspar; John B Fiveash; Veronica Chiang; Jonathan P S Knisely; Christina Maria Sperduto; Nancy Lin; Minesh Mehta Journal: Int J Radiat Oncol Biol Phys Date: 2011-04-15 Impact factor: 7.038
Authors: B Borgelt; R Gelber; S Kramer; L W Brady; C H Chang; L W Davis; C A Perez; F R Hendrickson Journal: Int J Radiat Oncol Biol Phys Date: 1980-01 Impact factor: 7.038
Authors: S N Sanghavi; S S Miranpuri; R Chappell; J M Buatti; P K Sneed; J H Suh; W F Regine; E Weltman; V J King; S J Goetsch; J C Breneman; P W Sperduto; C Scott; S Mabanta; M P Mehta Journal: Int J Radiat Oncol Biol Phys Date: 2001-10-01 Impact factor: 7.038
Authors: David W Andrews; Charles B Scott; Paul W Sperduto; Adam E Flanders; Laurie E Gaspar; Michael C Schell; Maria Werner-Wasik; William Demas; Janice Ryu; Jean-Paul Bahary; Luis Souhami; Marvin Rotman; Minesh P Mehta; Walter J Curran Journal: Lancet Date: 2004-05-22 Impact factor: 79.321
Authors: Li Gen Wang; Yan Guo; Xiang Zhang; Shao Jun Song; Jie Lai Xia; Feng Yun Fan; Mei Shi; Li Chun Wei Journal: Stereotact Funct Neurosurg Date: 2002 Impact factor: 1.875
Authors: Ahmed Alomari; Philipp J Rauch; Maria Orsaria; Frank J Minja; Veronica L Chiang; Alexander O Vortmeyer Journal: J Neurooncol Date: 2014-01-18 Impact factor: 4.130
Authors: A Serna; P P Escolar; V Puchades; F Mata; D Ramos; M A Gómez; A Iglesias; J Salinas; M Alcaraz Journal: Clin Transl Oncol Date: 2015-03-17 Impact factor: 3.405